2025-11-06 17:43:17
Latest Post
Avalon Technologies Ltd Q2FY26 consolidated net profit at Rs. 24.97 crores
CyberTech Systems and Software Ltd Q2 FY2025-26 consolidated profit at Rs. 8.65 crores
Piramal Pharma Ltd consolidated Q2FY26 loss at Rs. 99.22 crores
Syngene International Ltd Q2FY26 consolidated PAT declines to Rs. 67.1 crores
Magellanic Cloud Ltd Q2 FY2026 consolidated PAT at Rs. 27.61 crores
Stock Report
Alembic Pharmaceuticals Ltd Q2FY26 consolidated PAT rises to Rs. 183.71 crores
Posted On : 2025-11-04 21:24:22( TIMEZONE : IST )
Alembic Pharmaceuticals Limited has reported Consolidated financial results for the period ended September 30, 2025.
Financial Results (Q2 FY2026) - QoQ Comparison
The company has reported total income of Rs. 1917.06 crores during the period ended September 30, 2025 as compared to Rs. 1717.22 crores during the period ended June 30, 2025.
The company has posted net profit / (loss) of Rs. 183.71 crores for the period ended September 30, 2025 as against net profit / (loss) of Rs. 153.63 crores for the period ended June 30, 2025.
The company has reported EPS of Rs. 9.40 for the period ended September 30, 2025 as compared to Rs. 7.85 for the period ended June 30, 2025.
| Financials | Q2 FY2026 | Q1 FY2026 | % Change |
| Total Income | ₹ 1917.06 crs | ₹1717.22 crs |  11.64% |
| Net Profit | ₹183.71 crs | ₹153.63 crs | 19.58% |
| EPS | ₹9.40 | ₹7.85 | 19.75% |
Financial Results (Q2 FY2026) - YoY Comparison
The company has reported total income of Rs. 1917.06 crores during the period ended September 30, 2025 as compared to Rs.1664.72 crores during the period ended September 30, 2024.
The company has posted net profit / (loss) of Rs.183.71 crores for the period ended September 30, 2025 as against net profit / (loss) of Rs.153.14 crores for the period ended September 30, 2024.
The company has reported EPS of Rs.9.40 for the period ended September 30, 2025 as compared to Rs.7.79 for the period ended September 30, 2024.
| Financials | Q2 FY2026 | Q2 FY2025 | % Change |
| Total Income | ₹ 1917.06 crs | ₹1664.72 crs | 15.16% |
| Net Profit | ₹183.71 crs | ₹153.14 crs | 19.96% |
| EPS | ₹9.40 | ₹7.79 | 20.67% |
Financial Results (Half Year Ended FY2026) - YoY Comparison
The company has reported total income of Rs.3634.28 crores during the 6 Months period ended September 30, 2025 as compared to Rs.3228.55 crores during the 6 Months period ended September 30, 2024.
The company has posted net profit / (loss) of Rs.337.34 crores for the 6 Months period ended September 30, 2025 as against net profit / (loss) of Rs.287.69 crores for the 6 Months period ended September 30, 2024.
The company has reported EPS of Rs.17.25 for the 6 Months period ended September 30, 2025 as compared to Rs.14.64 for the 6 Months period ended September 30, 2024.
| Financials | Half Year Ended FY2026 | Half Year Ended FY2025 | % Change |
| Total Income | ₹3634.28 crs | ₹3228.55 crs | 12.57% |
| Net Profit | ₹337.34 crs | ₹287.69 crs | 17.26% |
| EPS | ₹17.25 | ₹14.64 | 17.83% |
Shares of Alembic Pharmaceuticals Limited was last trading in BSE at Rs. 960.10 as compared to the previous close of Rs. 924.30. The total number of shares traded during the day was 68650 in over 3379 trades.
The stock hit an intraday high of Rs. 998.00 and intraday low of 927.90. The net turnover during the day was Rs. 66562586.00.
